https://orcid.org/0000-0002-7464-8008
References
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi:10.1016/S0140-6736(17)31191-1.
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi:10.1056/NEJMoa1610020.
- Awosika O, Kim L, Mazhar M, Rengifo-Pardo M, Ehrlich A. Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol. 2018;11:41–49. doi:10.2147/CCID.S123329.
- Wollenberg A, Ariens L, Thurau S, van Luijk C, Seegraber M, de Bruin-Weller M. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018. doi:10.1016/j.jaip.2018.01.034.
- Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293–1300. doi:10.1016/j.jaci.2014.10.013.
- Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26(9):1176–1193. doi:10.1111/j.1468-3083.2012.04636.x.
- Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab. Am J Ophthalmol Case Rep. 2017;7:120–122. doi:10.1016/j.ajoc.2017.06.017.
- Two Phase. 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090–1091. doi:10.1056/NEJMc1700366.
- Eshtiaghi P, Gooderham MJ. Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid. 2018;13:13–20. doi:10.2147/CE.S133661.
- Yagi R, Nagai H, Iigo Y, Akimoto T, Arai T, Kubo M. Development of atopic dermatitis-like skin lesions in STAT6-Deficient NC/NGA mice. J Immunol. 2002;168:2020–2027.
- Cavani AAC, Traidl C, Sebastiani S, Girolomoni G. Effector and regulatory T cells in allergic contact dermatitis. Trends Immunol. 2001;22:118–120.
- Yokozeki H, Ghoreishi M, Takagawa S, et al. Signal transducer and activator of transcription 6 is essential in the induction of contact hypersensitivity. J Exp Med. 2000;191(6):995–1004.
- Amin KA. BD: the aetiology of eyelid dermatitis: a 10-year retroscpective analysis. Contact Dermatitis. 2006;55:280–285. doi:10.1111/j.1600-0536.2006.00927.x.